Thursday, January 07, 2021 6:30:52 AM
Collegium Pharmaceutical, Inc.
Wed, January 6, 2021, 4:01 PM EST
– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million –
– Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million –
– Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million –
STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.
“Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise. We delivered on our broad operational objectives and prioritized the health and safety of our people, customers and the communities that we serve,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “As we head into 2021, we remain steadfast in our commitment to being the leader in responsible pain management, maximizing the potential of our differentiated pain portfolio and creating value for our shareholders.”
“Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure,” said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium. “This year, we expect to generate significant cash flow from operations and will deploy our balance sheet in a disciplined manner that invests in the long-term growth of our company.”
Financial Guidance for 2021
Xtampza® ER revenues are expected in the range of $155.0 million to $165.0 million
Nucynta® franchise revenues are expected in the range of $175.0 million to $185.0 million
Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $160.0 million to $170.0 million
Total operating expenses are expected in the range of $125.0 million to $135.0 million
https://finance.yahoo.com/news/collegium-provides-2021-financial-guidance-210100747.html
Recent COLL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:32:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:39:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:06:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:52:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/06/2024 03:53:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 08:47:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 12:03:46 PM
- Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/15/2024 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 06:41:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 08:34:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:04:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:01:35 PM
- Collegium Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 10:02:38 AM
- Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology • GlobeNewswire Inc. • 07/29/2024 10:00:00 AM
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:05:25 PM
- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 08:50:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:06:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:36:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:22:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 05:59:12 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM